Is there a biosimilar for Epkinly?
What are Epkinly’s sales?
When was Epkinly approved?
No US biosimilar can be approved before 19 May 2035, when the 12-year US reference product exclusivity for Epkinly (epcoritamab-bysp) ends. Actual launch timing also depends on any patents and BPCIA patent litigation.
Yes. Epkinly (epcoritamab-bysp) is licensed by the FDA under a Biologics License Application (BLA), so follow-on versions would use the biosimilar (351(k), aBLA) pathway rather than an ANDA. A biosimilar application referencing it can be submitted from 19 May 2027, four years after its first licensure.
The most recent revenue figure for Epkinly (epcoritamab-bysp) is about $650M. Sales are projected to reach about $4.4B by 2032. The innovator is Genmab and AbbVie.
The FDA first licensed Epkinly (epcoritamab-bysp) on 19 May 2023. It is used to treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy. The innovator is Genmab and AbbVie and it is available as an injection.